GlassScriptPhysician profile
Ajay Verma
NPI 1578658886
$3,762.61
in general payments reported to CMS, 2019-2025
23 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $374 · 2021: $880 · 2022: $517 · 2023: $603 · 2024: $361 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,689.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $920.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.48 | 2019-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $320.68 | 2021-2025 | |
| Glaxosmithkline, LLC. | $295.50 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $288.65 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $203.22 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $150.98 | 2019-2022 | |
| Amgen INC. | $148.10 | 2020-2025 | Krystexxa, Otezla, Repatha |
| Vifor Pharma, INC. | $125.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $122.21 | 2025 | |
| Insmed, INC. | $121.34 | 2021 | |
| Pfizer INC. | $99.19 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $93.66 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $74.81 | 2019-2021 | |
| Abbvie INC. | $60.74 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51.49 | 2021-2022 | |
| Akebia Therapeutics INC | $42.64 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $38.37 | 2023-2024 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $30.84 | 2022 | |
| Abiomed | $28.09 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $25.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.22 | 2021 | |
| Merck Sharp & Dohme LLC | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.